retatrutide chest pain and Heart Issues: Cardiovascular Effects, Risks, and Safety – Bolt Pharmacy Chest Pain Localisation diagnosis Chest

Combined GI event rates in a dual-drug regimen would likely exceed either figure

Retatrutide is a synthetic triple-agonist peptide that acts on the GIP, GLP-1 and glucagon receptors simultaneously, making it a compound of significant interest in metabolic and receptor-signalling research models

According to the company, people with obesity and knee osteoarthritis taking retatrutide lost up to 71 pounds on average, or nearly 30% of their baseline weight

The trial included a 24-week extension period at doses of 9 or 12 mg for about 500 adults with a BMI of 35 or greater, which is classified as severe obesity

The MHRA and EMA will only issue formal prescribing guidance including interaction warnings once a medicine has been granted a marketing authorisation